Challenges of international oncology trial collaboration-a call to action.
Monica Tang , Heikki Joensuu , Robert J. Simes , Timothy J. Price
British Journal of Cancer 121 ( 7) 515 -521
3
2019
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
Maria Debiec-Rychter , Raf Sciot , Axel Le Cesne , Marcus Schlemmer
European Journal of Cancer 42 ( 8) 1093 -1103
1,014
2006
Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis
Stephen J Clarke , Sonia Yip , Chris Brown , Guy A van Hazel
European Journal of Cancer 47 ( 12) 1826 -1836
14
2011
Corrigendum to “Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis” [Eur J Cancer 47 (12) (2011) 1826–1836]
Stephen J. Clarke , Sonia Yip , Chris Brown , Guy A. van Hazel
European Journal of Cancer 48 ( 3) 407
2012
Phase II study of 10-EdAM in patients with squamous cell carcinoma of the head and neck, previously untreated with chemotherapy.
Michael D. Green , Peter Sherman , John Zalcberg
Investigational New Drugs 10 ( 1) 31 -34
8
1992
Peeling the Onion of Health Care Disparity in Lung Cancer
Rob Stirling , John Zalcberg
Journal of Thoracic Oncology 14 ( 8)
2019
Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer.
John Zalcberg
Anti-Cancer Drugs 8
30
1997
IN VITRO BINDING OF MX2 (KRN8602) AND EPIRUBICIN TO HUMAN PLASMA PROTEIN
Wei-zheng. Zhang , Walter Cosolo , John Zalcberg
Pharmacology 55 ( 6) 279 -284
1
1997
Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy.
Danielle Ferraro , John Zalcberg
Therapeutic Advances in Medical Oncology 6 ( 5) 222 -228
14
2014
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.
Paolo G Casali , John Zalcberg , Axel Le Cesne , Peter Reichardt
Journal of Clinical Oncology 35 ( 15) 1713 -1720
65
2017
Apparent T-cell neoplasms with immunoglobulin gene rearrangements.
Michael Friedlander , John Zalcberg , Bruce Patterson , Mark Minden
The Lancet 326 ( 8456) 670 -670
1
1985
Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer.
Kenneth Khamly , Michael Jefford , Michael Michael , John Zalcberg
Expert Opinion on Investigational Drugs 14 ( 6) 607 -628
16
2005
Recent developments in the systemic therapy of advanced gastroesophageal malignancies
Kenneth Khamly , Michael Jefford , Michael Michael , John Zalcberg
Expert Opinion on Investigational Drugs 15 ( 2) 131 -153
6
2006
Short-term outcome of emergency colorectal cancer surgery: results from Bi-National Colorectal Cancer Audit.
Chun Hin Angus Lee , Joseph Cherng Huei Kong , Alexander G Heriot , Satish Warrier
International Journal of Colorectal Disease 34 ( 1) 63 -69
6
2019
Effect of Aspirin on Cancer Incidence and Mortality in Older Adults.
John J McNeil , * Peter Gibbs , Suzanne G Orchard
Journal of the National Cancer Institute 113 ( 3) 258 -265
81
2021
Recent Advances in the Systemic Therapy of Metastatic Colorectal Cancer
Michael Jefford , John Zalcberg
American Journal of Cancer 4 ( 1) 15 -34
4
2005
Evidence-based adjuvant treatment of resectable pancreatic adenocarcinoma
Sherene Loi , Michael Findlay , John Zalcberg
American Journal of Cancer 4 ( 3) 159 -168
1
2005
Discussing expensive anticancer drugs.
Michael Jefford , Linda Mileshkin , Penelope Schofield , Emilia Agalianos
Journal of Clinical Oncology 27 ( 3) 476 -477
4
2009
Comment on: 'Hospital lung surgery volume and patient outcomes'.
Rob Stirling , Michael Stenger , John Zalcberg
Lung Cancer 142 138 -139
2020
Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance.
Yumiko Hirokawa , Melissa Arnold , Hidenori Nakajima , John Zalcberg
Cancer Biology & Therapy 4 ( 9) 956 -960
68
2005